Johnson & Johnson (J&J) has reported the latest data from a real-world study, where a single dose of its Covid-19 vaccine offered durable protection for up to six months against breakthrough Covid-19 infections and hospital and intensive care unit (ICU) admissions.
The Janssen Pharmaceutical Companies of J&J-sponsored study assessed durability by measuring the Odds Ratio (OR) of three Covid-19 vaccines that obtained authorisation or approval in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
OR indicates the odds of a completely inoculated person developing an outcome of breakthrough infection, hospitalisation, or admission to the ICU every month relative to the odds of having an outcome in the first month following full vaccination.
An OR, which is greater than one, represents the waning of the protection offered by the shot over time for the outcome.
In the first month following complete inoculation, the preliminary level of effectiveness was reported to be 81% for hospitalisations.
During the study, no evidence of reduced protection against Covid-19-linked hospitalisation and ICU admissions was observed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, a modest reduction in protection against breakthrough infection was observed in the fourth month.
Johnson & Johnson Janssen Research & Development Pharmaceuticals executive vice-president Mathai Mammen said: “While these are rapidly evolving data, we are seeing vaccine effectiveness against Covid-19-related hospitalisation of approximately 80% from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far – up to six months.
“We previously reported that our vaccine induces a strong antibody response, as well as an especially strong increase in T-cells, that is consistent across variants, including Omicron.”
Last month, J&J reported preliminary data from the Phase II COV2008 trial in which the booster dose of its Covid-19 vaccine, Ad26.COV2.S, provided increased antibody and T-cell responses when administered six months after the initial two-dose regimen with Pfizer-BioNTech’s BNT162b2 vaccine.
